Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer.

ABSTRACT:

Background

The HER family of proteins (EGFR, HER2, HER3 and HER4) have long been thought to be therapeutic targets for bladder cancer, but previous clinical trials targeting these proteins have been disappointing. Second generation agents may be more effective.

Objective

The aim of this study was to evaluate responses to two second-generation irreversible tyrosine kinase inhibitors, dacomitinib and afatinib, in bladder cancer cell lines.

Methods

Cell lines were characterized by targeted next generation DNA sequencing, RNA sequencing, western blotting and flow cytometry. Cell survival responses to dacomitinib or afatinib were determined using (3-[4,5-dimethylthioazol-2-yl]-2,5-diphenyl tetrazolium bromide) (MTT) or [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxypheny

SUBMITTER: Tamura S 

PROVIDER: S-EPMC5798519 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature